Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

T. MinDiabetes Research Group, School of Medicine, Swansea University, Swansea, Wales, UK;Department of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

L. WaliDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

D.M. WilliamsDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

E. PlummerDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

A. GurungDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK

J.W. StephensDepartment of Diabetes & Endocrinology, ABM University Health Board, Swansea, Wales, UK;Diabetes Research Group, School of Medicine, Grove Building, Swansea University, Swansea SA6 8NL, Wales, UKCorrespondence[email protected]

References

Mende CW. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Curr Med Res Opin 2017;33:541-551
PubMed Web of Science ®Google Scholar
Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
PubMed Web of Science ®Google Scholar
Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-36
PubMed Web of Science ®Google Scholar
Bloomgarden Z. Sodium–glucose cotransporter 2 inhibitors and renal function – 2. J Diabetes 2015;7:295-8
PubMed Web of Science ®Google Scholar
NICE. Dapagliflozin in combination therapy for treating type 2 diabetes: TA288. 2013. Available at: http://www.nice.org.uk/guidance/ta288/resources/guidance-dapagliflozin-in-combination-therapy-for-treating-type2-diabetes-pdf
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dapagliflozin and renal function. Re: Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Mende CW. Curr Med Res Opin 2017;33:541-551

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date